FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the ...

BridgeBio Pharma's robust pipeline, favorable policy shifts, and milestone payments position it for substantial future growth ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis ...

Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

Pfizer has increased its dividend for 16 straight years, and its dividend yield was recently a fat 7.1%, meaning that a $1,000 position in the stock would generate $71 over a year.

Stocks like Pfizer, Amgen, Johnson & Johnson, and Eli Lilly & Co. were among others which opened lower after the US stock market opened on Wednesday. Pfizer Inc. shares are currently trading 2.56 ...

Pfizer Inc.’s longtime chief scientist is joining Blackstone Inc. to advise the private equity giant on its investments into advanced new medicines. Mikael Dolsten, who retired from Pfizer late ...

The ability to accurately predict survival/life expectancy in ATTR-CM can better inform clinical decision-making. In incurable illnesses of which prognosis is poor, the ability to provide patients ...

Pfizer is one of the world’s largest pharmaceutical companies, with annual sales above $63 billion in 2024. Shares are down approximately 20% year-to-date. UBS analyst Trung Huynh maintained ...

The firm’s analysts demonstrated confidence in the revenue potential of AMVUTTRA®, mainly in the treatment of ATTR-CM, which is a heart condition caused by transthyretin-mediated amyloidosis.

Pfizer has a very low valuation and a sky-high dividend yield. But this could be a broken stock, not so much a broken company. Pfizer's product sales could churn as patents expire, but the stock ...